kabutan

Kubota Pharmaceutical Holdings Co., Ltd.(4596) Summary

4596
TSE Growth
Kubota Pharmaceutical Holdings Co., Ltd.
94
JPY
-5
(-5.05%)
Jan 29, 1:37 pm JST
0.61
USD
Jan 28, 11:37 pm EST
Result
PTS
outside of trading hours
94
Jan 29, 1:38 pm JST
Summary Chart Historical News Financial Result
PER
PBR
6.26
Yield
ー%
Margin Trading Ratio
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
104 JPY 0.67 USD
Previous Close Jan 28
99 JPY 0.64 USD
High Jan 29, 9:00 am
106 JPY 0.69 USD
Low Jan 29, 9:17 am
90 JPY 0.58 USD
Volume
8,505,500
Trading Value
0.82B JPY 5.37M USD
VWAP
96.54 JPY 0.63 USD
Minimum Trading Value
9,400 JPY 61 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
1,736
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
523
1-Year High Sep 3, 2025
18,100
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 14,500 4,865,500 335.55
Jan 16, 2026 0 3,699,400
Jan 9, 2026 0 3,284,000
Dec 26, 2025 0 3,227,200
Dec 19, 2025 0 3,426,400
Company Profile
Kubota Pharmaceutical Holdings Co., Ltd. is a venture company focused on developing treatments for eye diseases. The company is currently concentrating on developing corrective glasses for myopia. Drug development projects have been suspended.
Sector
Pharmaceuticals
Kubota Pharmaceutical Holdings Co., Ltd. is committed to developing innovative treatments and medical technologies as an ophthalmic medical solutions company. The company aims to contribute to maintaining and restoring vision for patients with eye diseases by developing and commercializing innovative pharmaceuticals and medical devices. Their main focus is in the medical device field, with emphasis on the "Kubota Glass," a wearable device for myopia control using proprietary active stimulation technology. They are also developing "eyeMO," an ultra-compact OCT for home-based ophthalmic care. In the small molecule compound area, they are advancing the development of emixustat hydrochloride as a treatment for Stargardt disease, based on visual cycle modulation technology. The company is actively pursuing partnership strategies with other companies to expand their pipeline and is also exploring M&A opportunities.